Abliva Appoints Dag Nesse as Vice President of Clinical Operations
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the appointment of Dag Nesse as Vice President of Clinical Operations. Mr. Nesse will join the company’s management team.
As a clinical company now progressing late stage studies, the recruitment of Mr. Nesse enables Abliva to further enhance its capabilities in clinical operations and continue to strengthen its management team. In this newly created role, Mr. Nesse will be responsible for the operational aspects of all clinical studies, including the FALCON study, the initiation of which was announced in December 2022, while also partnering with Magnus Hansson, CMO, on the broader overall clinical strategy for KL1333 and NV354.
Mr. Nesse comes to Abliva with a wealth of experience in clinical operations across all stages of development, including leadership from pivotal study to data readout, marketing authorization, and launch. Most recently Director, Clinical Operations at EpiEndo, Mr. Nesse was previously Head of Clinical Operations at Calliditas Therapeutics AB and earlier the Head of Clinical Operations at Modus Therapeutics AB, both rare disease companies based in Stockholm, Sweden. Mr. Nesse is a registered nurse and has a degree from the Norwegian Business School and a degree in Sociology from the University of Oslo.
“I am excited to be joining this driven team at such an important time for the company. Given the data seen in the first patient study, KL1333 can make a significant difference in the lives of people suffering from Primary Mitochondrial disease. I am looking forward to working with the Abliva team to deliver this important study with the rigor required of a registrational study,” said Mr. Nesse.
“I am happy to welcome Dag to Abliva where he will be responsible for the operational aspects of our clinical studies. He will also contribute to the strategy and growth of the company as we prepare for the next stage of our development: the readout of the registrational study and the potential approval and commercialization of our lead asset,” said Ellen Donnelly, CEO.
